secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2022-08-23T23:59:59+00:00
Accession:  0001104659-22-093694
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva files risk factor update with no specific new disclosure
-----------------------------------------------------------------

- Filed an 8-K to supplement risk factors from its June 30, 2022 10-Q and 2021 10-K.
- Updated risk factors cover clinical trial failure, patient enrollment delays, and third-party dependence.
- No specific new events, financial results, or business developments were reported.
- The risk factor language is standard biotech boilerplate with no material changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/0001104659-22-093694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922093694/tm2224315d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-093694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer